Skip to main content

Table 2 Relationship between pathological characteristics and PD-L1 and PD-1 expression in intrahepatic cholangiocarcinoma

From: Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients

  n PD-L1 expression PD-1 expression
Cancerous cell (+) p value Stromal cells (+) p value Lymphocyte (+) p value
Tumor size, cm    0.806   0.9   0.034
 > 5 cm 33 3 (9.1%)   17 (51.5%)   6 (18.2%)  
 ≤ 5 cm 36 5 (13.9%)   18 (50%)   15 (41.7%)  
Tumor number    0.812   0.348   0.499
 Single 54 6 (11.1%)   29 (53.7%)   18 (33.3%)  
 Multiple 15 2 (13.3%)   6 (40%)   3 (20%)  
Gross types    0.186   0.348   0.22
 MF 54 8 (14.8%)   29 (53.7%)   14 (25.9%)  
 Non-MF 15 0 (0)   6 (40%)   7 (46.7%)  
Differentiation    0.043   0.308   0.408
 Well   0 (0)   1 (2.8%)   1 (4.8%)  
 Moderately   5 (63%)   29 (82.9%)   19 (90.4%)  
 Poorly or undifferentiated   3 (37%)   5 (14.3%)   1 (4.8%)  
CLC or cICC 14 3 (21.4%) 0.412 9 (64.3%) 0.256 3 (21.4%) 0.621
 MVI 25 4 (16%) 0.638 0 (0) 0.199 4 (16%) 0.005
 Neural invasion 69 8 (11.6%) 0.227 35 (50.7%) 0.988 21 (30.4%) 1.0
TNM stage    0.245   0.429   0.282
 I 28 1 (3.6%)   6 (21.4%)   8 (28.6%)  
 II 25 5 (20%)   13 (52%)   6 (24%)  
 III 5 1 (20%)   2 (40%)   1 (20%)  
 IV 11 1 (9.1%)   6 (54.5%)   6 (54.5%)  
Breakthrough the liver 12 1 (8.3%) 0.698 6 (50%) 0.956 3 (25%) 0.916
Grade of inflammation    0.961   0.504   0.853
 G0,G1or G2 60 7 (11.7%)   29 (48.3%)   19 (31.7%)  
 G3 or G4 9 1 (11.1%)   6 (66.7%)   2 (22.2%)  
Fibrosis/cirrhosis    0.012   0.77   0.686
 S0,S1 or S2 59 4 (6.78%)   29 (49.2%)   19 (32.2%)  
 (S3 or S4) 10 4 (40%)   6 (60%)   2 (20%)  
CD8 density/Hp
 CD8+ TIL ≥ 40 4 4 (100%)  < 0.0001 4 (100%)   1 (25%)  
 CD8+ NIL ≥ 40 19 6 (31.6%)  < 0.0001 13 (68.4%)   8 (42.1%)  
  1. MF mass-forming, CLC Cholangiolocellular Carcinoma, cICCconventional Intrahepatic Cholangiocarcinoma, MVI microvascular invasion